What is it that the PBM industry doesn’t want you to know?” asked the CEO of the Florida Pharmacy Association.

Ed Kaplan, the national health practice leader at Segal, also has concerns about "any willing provider" strategies.

Another pressing concern for participants was the rise in drug costs, with 54% expecting at least half of U.S. states to establish drug-affordability boards. Additionally, 97% foresee a 25% surge in ...

Policymakers at the federal and state level have considered a number of reforms, many of which have bipartisan support, to ...

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...